VitaDX is very pleased to announce the signing of a partnership with Cerba Healthcare as part of the validation of the VisioCyt® test for early diagnosis of bladder cancer. This collaboration will allow VitaDX to refine its market access strategy and the commercial deployment of its first product VisioCyt®.

At the end of the clinical validation, Cerba Healthcare will benefit from an exclusivity to carry out the test developed by VitaDX in 4 strategic geographical areas: France, Belgium, Luxembourg and United Arab Emirates.

Read the press release